Deignan Charles A.'s Form 4/A amendment
AmendedClearside Biomedical, Inc. (CLSD) · filed Jan 28, 2022
- Accession no.
- 0001209191-22-005437
- Filed
- Jan 28, 2022
- Trade date
- Jan 18, 2022
- Filing delay
- 10 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Jan 20, 2022
This filing lists 1 non-derivative transaction and 1 derivative transaction. It carries over 1 transaction from the original filing that it did not restate. Open-market sales total $18.5K. It was filed 10 days after the trade.
This amendment restates part of 0001209191-22-004194 (filed Jan 20, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deignan Charles A.CIK 0001664690 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 18, 2022 | Common Stock | AGrant or awardAcquired | +46,250 | $0.00 | $0 | 362,699 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 18, 2022 | Common Stock | AGrant or awardAcquired | +138,750 | $0.00 | $0 | 138,750 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001209191-22-004194 (filed Jan 20, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 19, 2022 | Common Stock | SSaleDisposed | −8,833 | $2.09F3 | −$18,460.97 | 351,366 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.0902 to $2.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
These shares are represented by restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of common stock of the Issuer. The shares underlying the RSU vest in 4 equal annual installments on each of January 18, 2023, January 18, 2024, January 18, 2025 and January 18, 2026, subject to the Reporting Person's continuous service as of each such vesting date.
- F2
One-fourth of the shares underlying this option vest on January 18, 2023 and the balance of the shares vest in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such vesting date.
Remarks
This amendment to the Reporting Person's Form 4 filed with the Securities and Exchange Commission on January 20, 2022 is being filed to correct the total number of stock options and restricted stock units awarded to the Reporting Person on January 18, 2022. Based on the foregoing, the total number of shares beneficially owned following the reported transactions should have been 353,866 instead of 351,366.